martes, 29 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

View original at finance.yahoo.com
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech plans to initiate six additional Phase 3 clinical trials in 2026, bringing the total number of anticipated Phase 3 clinical trials to 15 by year end

    80% confidence

  • BioNTech has more than ten novel-novel combination clinical trials in its pipeline with multiple data updates expected in 2026

    80% confidence

  • BioNTech does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026

    80% confidence

  • 2026 is poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies

    80% confidence

  • Revenues to BioNTech from the collaboration with BMS in 2026 are expected to be broadly in line with 2025

    80% confidence

  • BioNTech expects at least 17 late-stage data readouts, including from pivotal trials, by 2030+

    80% confidence

  • BioNTech has more than doubled the number of Phase 2 and 3 oncology trials across key modalities within the past two years, with now more than 25 Phase 2 or 3 trials ongoing

    80% confidence

  • BioNTech expects seven late-stage data readouts in 2026

    80% confidence

  • BioNTech anticipates a modest decline in Comirnaty revenues compared to 2025, reflecting COVID-19 vaccine market dynamics

    80% confidence

  • 2026 will be a year when science translates into tangible results with readouts from late-stage trials and earlier trials evaluating novel-novel combinations

    80% confidence

Data points we hold from this source

BioNTech SE · phase 3 trials9 trials
BioNTech SE · novel novel combination trials10 trials
BioNTech SE · phase 2 3 trials25 trials
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,314 documentos fuente archivados
Consulta estos datos → isubstrate.com
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference — Source | Via News | es.VIA.NEWS